Abstract:Targeting proteins' enzymatic functions with small molecule inhibitors, as well as functions of receptor proteins with small-molecule agonists and antagonists, were the major forms of small-molecule drug development. These small-molecule modulators are based on a conventional occupancy-driven pharmacological approach. For proteome space traditionally considered undruggable by small-molecule modulators, such as enzymes with scaffolding functions, transcription factors, and proteins that lack well-defined binding pockets for small molecules, targeted protein degraders offer the opportunity to drug the proteome with an event-driven pharmacological approach. A degrader molecule, either PROTAC or molecular glue, brings the protein of interest (POI) and E3 ubiquitin ligase in close proximity and engages the ubiquitin-proteasome system (UPS), the cellular waste disposal system for the degradation of the POI. For the development of targeted protein degraders to meet therapeutic needs, several aspects will be considered, namely, the selective degradation of disease-causing proteins, the oral bioavailability of degraders beyond Lipinski's rule of five (bRo5) scope, demands of new E3 ubiquitin ligases and molecular glue degraders, and drug resistance of the new drug modality. This review will illustrate several under-discussed key considerations in targeted protein degradation drug discovery and development: 1) the contributing factors for the selectivity of PROTAC molecules and the design of PROTACs to selectively degrade synergistic pathological proteins; 2) assay development in combination with a multi-omics approach for the identification of new E3 ligases and their corresponding ligands, as well as molecular glue degraders; 3) a molecular design to improve the oral bioavailability of bRo5 PROTACs, and 4) drug resistance of degraders.

The new direction of drug development: Degradation of undruggable targets through targeting chimera technology

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeting the Undruggables ---- the Power of Protein Degraders

Protein degradation technology: a strategic paradigm shift in drug discovery.

Recent advances in targeted protein degraders as potential therapeutic agents

Targeted protein degradation in drug development: Recent advances and future challenges

Major Advances in Emerging Degrader Technologies.

Targeted Protein Degradation: Principles, Strategies, and Applications

Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery

Chimera induced protein degradation: PROTACs and beyond

Key Considerations in Targeted Protein Degradation Drug Discovery and Development

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

The state of the art of PROTAC technologies for drug discovery

Targeted protein degradation: mechanisms, strategies and application

Nucleic-Acid-Based Targeted Degradation in Drug Discovery

Emerging Targeted Protein Degradation Tools for Innovative Drug Discovery: from Classical PROTACs to the Novel and Beyond.

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Protein degradation as an innovative strategy in drug discovery

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

Bivalent Ligands for Protein Degradation in Drug Discovery